Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CU-40101 in Male Androgenic Alopecia
NCT05380427Phase 1Completed
- Sponsor
- Cutia Therapeutics
- Start
- Aug 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TDM-105795 in androgenetic alopecia (AGA) (8 arms), sponsored by Cutia Therapeutics. Primary endpoints: Adverse Events and Serious Adverse Events, Vital signs and 3 more. Started Aug 2022; status: completed.
02
Drugs
TDM-105795
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT05380427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05380427.